Spyre Therapeutics Inc. SYRE

NAS: SYRE | ISIN: US00773J2024   31/05/2024
34,95 USD (+2,64%)
(+2,64%)   31/05/2024

29 mei 2024 · Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference · Persbericht

15 mei 2024 · Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors · Persbericht

9 mei 2024 · Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

3 mei 2024 · Spyre Therapeutics Announces Grants of Inducement Awards · Persbericht

1 april 2024 · Spyre Therapeutics Announces Grants of Inducement Awards · Persbericht

18 maart 2024 · Spyre Therapeutics Announces $180 Million Private Placement · Persbericht

1 maart 2024 · Spyre Therapeutics Announces Grants of Inducement Awards · Persbericht

29 februari 2024 · Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update · Persbericht

26 februari 2024 · Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference · Persbericht

8 februari 2024 · Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation · Persbericht

5 februari 2024 · Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors · Persbericht

2 februari 2024 · Spyre Therapeutics Announces Grants of Inducement Awards · Persbericht

22 december 2023 · Spyre Therapeutics Announces Grants of Inducement Awards · Persbericht

8 december 2023 · Spyre Therapeutics Announces $180 Million Private Placement · Persbericht

Mijn selecties